|
Jul 24
|
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
|
|
Jul 21
|
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
|
|
Jun 18
|
We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate
|
|
Mar 13
|
Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock
|
|
Mar 13
|
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
|
|
Mar 12
|
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
|
|
Feb 26
|
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
|